Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

FDA releases statement on the efficacy of Lartruvo®

April 12, 2019

On January 24, 2019, the U.S. Food and Drug Administration (FDA) released a statement regarding the efficacy of the drug Lartruvo® (olaratumab). Lartruvo® was approved by the FDA in October 2016, to treat soft tissue sarcoma, in combination with doxorubicin. A long-term clinical study has found that treatment with Lartruvo® and doxorubicin did not meet the primary endpoint of improvement in overall survival compared with a placebo and doxorubicin. Additionally, the National Comprehensive Cancer Network has removed the combination regimen of Lartruvo® and doxorubicin as a recommended therapy in their Soft Tissue Sarcoma guidelines.

Effective April 12, 2019, Independence will no longer consider Lartruvo® as medically necessary for treatment of soft tissue sarcoma in combination with doxorubicin. In accordance with the FDA statement, providers who are currently treating Independence members with Lartruvo® should speak with them about the feasibility of continued treatment with the drug. An Independence medical policy on Lartruvo® is currently in development.

For more information

The complete statement on Lartruvo® is available on the FDA website. If you have any questions about this update, please email us at provider_communications@ibx.com.


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.